These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37827864)

  • 21. Combination Immunotherapy With LIGHT and Interleukin-2 Increases CD8 Central Memory T-Cells In Vivo.
    Fernandez MF; Qiao G; Tulla K; Prabhakar BS; Maker AV
    J Surg Res; 2021 Jul; 263():44-52. PubMed ID: 33631377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells.
    Vazquez-Lombardi R; Loetsch C; Zinkl D; Jackson J; Schofield P; Deenick EK; King C; Phan TG; Webster KE; Sprent J; Christ D
    Nat Commun; 2017 May; 8():15373. PubMed ID: 28497796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suppression of allograft rejection by CD8+CD122+PD-1+ Tregs is dictated by their Fas ligand-initiated killing of effector T cells versus Fas-mediated own apoptosis.
    Liu H; Wang Y; Zeng Q; Zeng YQ; Liang CL; Qiu F; Nie H; Dai Z
    Oncotarget; 2017 Apr; 8(15):24187-24195. PubMed ID: 28445940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
    Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
    Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonhuman Primate Testing of the Impact of Different Regulatory T Cell Depletion Strategies on Reactivation and Clearance of Latent Simian Immunodeficiency Virus.
    Sivanandham R; Kleinman AJ; Sette P; Brocca-Cofano E; Kilapandal Venkatraman SM; Policicchio BB; He T; Xu C; Swarthout J; Wang Z; Pandrea I; Apetrei C
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aptamer-Targeted Attenuation of IL-2 Signaling in CD8
    Rajagopalan A; Berezhnoy A; Schrand B; Puplampu-Dove Y; Gilboa E
    Mol Ther; 2017 Jan; 25(1):54-61. PubMed ID: 28129128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy.
    Hinrichs CS; Spolski R; Paulos CM; Gattinoni L; Kerstann KW; Palmer DC; Klebanoff CA; Rosenberg SA; Leonard WJ; Restifo NP
    Blood; 2008 Jun; 111(11):5326-33. PubMed ID: 18276844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Soluble γc receptor attenuates anti-tumor responses of CD8
    Kim G; Hwang H; Jo Y; Lee B; Lee YH; Kim CH; Hong C
    Int J Cancer; 2018 Sep; 143(5):1212-1223. PubMed ID: 29577276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prophylactic and Therapeutic Effects of Interleukin-2 (IL-2)/Anti-IL-2 Complexes in Systemic Lupus Erythematosus-Like Chronic Graft-Versus-Host Disease.
    Heiler S; Lötscher J; Kreuzaler M; Rolink J; Rolink A
    Front Immunol; 2018; 9():656. PubMed ID: 29670626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.
    Maas RA; Roest PA; Becker MJ; Weimar IS; Dullens HF; Den Otter W
    Immunobiology; 1992 Nov; 186(3-4):214-29. PubMed ID: 1490728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.
    Shen L; Ciesielski M; Ramakrishnan S; Miles KM; Ellis L; Sotomayor P; Shrikant P; Fenstermaker R; Pili R
    PLoS One; 2012; 7(1):e30815. PubMed ID: 22303460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-dose cyclophosphamide combined with IL-2 inhibits tumor growth by decreasing regulatory T cells and increasing CD8+ T cells and natural killer cells in mice.
    Tang F; Zhong Q; Yang Z; Li H; Pan C; Huang L; Ni T; Deng R; Wang Z; Tan S; Nie Y; Zhang Y
    Immunobiology; 2022 May; 227(3):152212. PubMed ID: 35436750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
    Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
    Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.
    Kim MT; Richer MJ; Gross BP; Norian LA; Badovinac VP; Harty JT
    J Immunol; 2015 Nov; 195(9):4537-44. PubMed ID: 26408669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MK-6, a novel not-α IL-2, elicits a potent antitumor activity by improving the effector to regulatory T cell balance.
    Kobayashi M; Kojima K; Murayama K; Amano Y; Koyama T; Ogama N; Takeshita T; Fukuhara T; Tanaka N
    Cancer Sci; 2021 Nov; 112(11):4478-4489. PubMed ID: 34545658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of T cell responses by IL-2 and IL-2 complexes.
    Boyman O; Kolios AG; Raeber ME
    Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S54-7. PubMed ID: 26457438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity.
    Zammarchi F; Havenith K; Bertelli F; Vijayakrishnan B; Chivers S; van Berkel PH
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32912922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
    Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY
    Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IL-21 promotes differentiation of naive CD8 T cells to a unique effector phenotype.
    Casey KA; Mescher MF
    J Immunol; 2007 Jun; 178(12):7640-8. PubMed ID: 17548600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8
    Hernandez R; Toomer KH; Põder J; Santos Savio A; Hsiung S; Malek TR
    Cancer Immunol Immunother; 2021 Apr; 70(4):909-921. PubMed ID: 33037893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.